KIDNEY-ONC 2001 KCA Convention Notes
The Boyle Authorized Version
Introduction and Disclaimer

The following notes were taken by PJ Boyle during the 2001 Kidney Cancer Association convention in San Francisco, CA, July 20-22. These notes are provided to allow non-attendees to get an overview of material presented at the conference, but they have not been approved by the speaker, the KCA, or anyone else. I am a patient, not a medical professional, and despite best efforts, I cannot guarantee that every detail was captured perfectly. Furthermore, optimal treatment of kidney cancer is often controversial, and you should not take what you find here to be the final word on any subject. If you have specific questions, particularly about therapies mentioned, I would encourage you to contact the speaker directly for more detail. Input from other attendees to either make corrections or augment the content is encouraged.

Editing and HTML by Steve Dunn. Occasional "Editor's notes" appear in red

2001 Presentations

"Overview of Therapies Treating Metastatic Renal Cell Carcinoma", Ronald Bukowski, MD
"Stem Cell Transplants in Kidney Cancer", John Thompson, MD
"Report of the Cytokine Working Group on Results of High Dose IL-2 versus Subcutaneous IL-2/Interferon in Patients with Renal Cell Carcinoma", Janice Dutcher, MD
"Heat Shock Protein", Robert Amato, DO
"Update On Vaccines", David Minor, MD
"Angiozyme: A New Approach in Treating Renal Cell Carcinoma", Janice Dutcher MD
"Thalidomide and Other Angiogenesis Agents", Robert Amato, DO
"Overview of Surgical Issues in the Treatment of Renal Cell Carcinoma", David Swanson, MD
"Surgical Innovations in the Treatment of Renal Cell Carcinoma" Christopher Wood, MD
"Nutrition, Diet, and Good Kidney Health", Marty Loeffler, RD
"IL-18, Another Frontier", Jonathan Wigginton, MD
"Immunologic Basis of Immunotherapy in Renal Cell Carcinoma", James Finke, Ph.D.

This Kidney Cancer FAQ Page By PJ Boyle. Copyright 2001 PJ Boyle
Last Updated August 3, 2001